Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals has been awarded a five-year, $32 million contract from the US National Institute of Allergy and Infectious Diseases for the development of therapeutic HIV vaccines.
Subscribe to our email newsletter
The research and development is to be conducted in conjunction with researchers at the University of Pennsylvania, Duke University, and Beth Israel/Deaconess Hospital in Boston.
Wyeth will develop and clinically evaluate novel adjuvant-enhanced plasmid DNA and peptide based vaccines for use in a prime-boost therapeutic regimen to help treat HIV infection. Previously, the National Institutes of Health (NIH) had awarded Wyeth two five-year contracts to evaluate two separate preventative HIV vaccine strategies.
NIH will provide the funding for direct costs associated with the design, manufacture and release of the clinical trial materials. Wyeth will contribute a minimum of $23 million of in-kind services.
“The Wyeth HIV vaccine program is focused on the identification and clinical evaluation of vaccine approaches capable of eliciting robust and sustained anti-HIV immunological responses,” says Dr Emilio Emini, executive vice president, Wyeth Vaccines R&D.